21 CFR § 207.33
FDA's Part 207 framework covers Labeler Code requests as part of the NDC and drug-listing system.
FDA Labeler Code Instructions →A Labeler Code is the FDA-assigned first segment used to create National Drug Codes (NDCs). FDA requires a company to have a Labeler Code before it can list a drug or reserve an NDC for the first time. The code identifies the company marketing the drug; FDA says generally drug manufacturers and distributors need one, while a company that does not manufacture or distribute drugs in the United States should not apply. A separate Labeler Code is not required for every manufacturing establishment under the same company.
We prepare the Labeler Code SPL request, verify the company/DUNS information, submit the filing through the current FDA electronic workflow, track the request, and complete the post-assignment confirmation step needed before downstream drug listing.
FDA's current instructions describe the Labeler Code as the company identifier used to propose and assign NDCs. A company is not required to obtain a separate Labeler Code for every manufacturing establishment under the same ownership because the Labeler Code identifies the company marketing the drug rather than each physical site.
That distinction matters when a product involves a contract manufacturer, repacker, relabeler, private-label distributor, or multiple establishments. The company/establishment roles should be mapped before requesting the code so the downstream NDC and drug-listing submissions use the correct parties.
FDA currently says that generally only drug manufacturers and distributors need a Labeler Code, and a company that does not manufacture or distribute drugs in the United States should not apply. The exact role should be reviewed before filing.
A Labeler Code request is an SPL submission. The filing should be built around the correct marketing company and the current FDA drug-listing workflow.
The Labeler Code identifies the company marketing the drug, so the request must use the company that will hold and use the code.
The request is created as a Structured Product Labeling document using the applicable FDA electronic submission workflow.
FDA's current instructions require an updated Labeler Code form SPL after assignment with the new code entered to complete the process.
The Labeler Code is only one step. Drug listing/NDC data, establishment information, labeling, and marketing status must still be handled correctly.
Labeler Codes sit inside the broader NDC and drug-listing framework.
The process is not complete when FDA merely assigns a number — the assigned code must be confirmed through the updated Labeler Code SPL before downstream listing use.
Confirm the legal company, DUNS, manufacturer/distributor role, products, existing FDA records, and whether a Labeler Code is actually required.
Prepare the Labeler Code request SPL with required company/contact information and submit it through the current FDA electronic workflow.
Monitor the request, receive the assigned code, and submit the updated Labeler Code SPL with the assigned number to complete the process.
Use the completed Labeler Code in the appropriate NDC reservation or drug-listing workflow and maintain the related FDA records over time.
Labeler Code assignment is part of the broader drug registration/listing framework and does not determine whether the drug is approved or otherwise lawfully marketed.
FDA's Part 207 framework covers Labeler Code requests as part of the NDC and drug-listing system.
FDA Labeler Code Instructions →Part 207 governs establishment registration, drug listing, Labeler Codes, NDCs, electronic submission requirements, and related updates.
Read 21 CFR Part 207 →FDA expressly warns that establishment registration or assignment of an NDC does not denote approval of the company or its products.
FDA Drug Registration & Listing →The standard scope focuses on the Labeler Code request and confirmation process. Other drug-registration/listing services are handled separately when needed.
Review whether the company is the appropriate manufacturer/distributor/marketing entity to request and use the Labeler Code.
Review the company name, DUNS information, and responsible contact data used in the Labeler Code request.
Prepare the initial Labeler Code request in the required Structured Product Labeling format.
Submit the request through the appropriate FDA drug registration/listing electronic workflow.
Track the request and address submission validation or administrative questions within the agreed scope.
Monitor for FDA's assignment communication and confirm the assigned Labeler Code.
Prepare and submit the updated Labeler Code form SPL with the assigned code to complete the process.
Identify the next NDC reservation, drug listing, establishment registration, labeling, or maintenance step based on the client's situation.
These identifiers serve different regulatory purposes and should not be substituted for one another.
| Labeler Code | NDC | FEI | |
|---|---|---|---|
| Identifies | The company marketing the drug | The drug product/package through its three NDC segments | An FDA-identified establishment/facility |
| Assigned By | FDA | FDA assigns the Labeler Code; product/package segments are proposed/assigned within the listing framework | FDA |
| Needed For | Before first listing or NDC reservation requiring a Labeler Code | Drug listing/product identification | Establishment identification |
| FDA Approval? | No | No | No |
Bottom line: a Labeler Code identifies the marketing company; an FEI identifies an establishment; and the full NDC identifies the listed drug/product package configuration.
FDA explicitly says a separate Labeler Code is not required for each establishment manufacturing drugs under that Labeler Code.
| Company / Labeler | Physical Drug Establishment | |
|---|---|---|
| Identifier Focus | Labeler Code identifies the company marketing the drug. | Establishment registration identifies the physical site and operations. |
| Multiple Locations | A manufacturer with multiple establishments can generally use one Labeler Code. | Each establishment subject to registration is handled based on its own physical location/operations. |
| DUNS Context | Labeler Code request includes the company's DUNS information. | Establishment registration uses the DUNS associated with the actual establishment location. |
| Foreign U.S. Agent | Not created merely by having a Labeler Code. | A covered foreign drug establishment has a separate U.S. Agent requirement. |
FDA finalized the long-term NDC format change in 2026, but the new native 12-digit format is not yet in effect.
| Current / Transition Period | Beginning March 7, 2033 | |
|---|---|---|
| FDA-Assigned Native NDC | 10-digit NDCs in current formats | Uniform 12-digit format |
| Format | Current 4-4-2, 5-3-2, or 5-4-1 configurations | 6-4-2: six-digit Labeler Code segment, four-digit product segment, two-digit package segment |
| Existing NDCs | Continue under the current system during the transition | FDA will convert previously assigned 10-digit NDCs to the uniform 12-digit format |
| Action Now | Use current FDA requirements and prepare systems/labeling for the future transition | Use the new native 12-digit format under the final rule |
The 12-digit rule does not make today's FDA-assigned NDCs 12 digits yet. FDA says the new format takes effect March 7, 2033.
These terms separate the company identifier from the establishment, product, and electronic submission records.
FDA-assigned first segment used to create National Drug Codes and identify the company marketing the drug.
National Drug Code — FDA's three-segment drug identifier consisting of Labeler Code, product code, and package code.
Structured Product Labeling — the XML format FDA uses for drug registration/listing submissions, including Labeler Code requests.
FDA's web-based SPL authoring platform. It includes the CDER Direct drug-submission functionality.
The drug-focused FDA Direct functionality used for drug registration/listing submissions, including NDC Labeler Code requests.
Data Universal Numbering System identifier used by FDA in drug registration/listing workflows, including Labeler Code requests.
Facility Establishment Identifier — FDA's identifier for an establishment; it is not a substitute for a Labeler Code.
The second segment of the NDC identifying a specific product/strength/dosage form/formulation for the labeler.
The third segment of the NDC identifying package size/type.
A persistent SPL identifier that is retained when creating updated versions of the same Labeler Code submission.
The SPL submission containing the drug's NDC, ingredients, labeling, establishments, marketing information, and other required listing data.
FDA workflow allowing an assigned Labeler Code holder to reserve an NDC product code before full drug listing when the applicable requirements are met.
Most issues come from the wrong company role, inconsistent identifiers, an incomplete post-assignment step, or confusing administrative identifiers with FDA approval.
The filing is submitted for an entity that does not actually need to list or reserve NDCs, while the correct marketing/manufacturing/distributing company is left unresolved.
The company identity and DUNS information used in the SPL do not align with the entity that will hold and use the Labeler Code.
FDA's current instructions require an updated Labeler Code form SPL with the assigned number to complete the process before drug listing under the code.
FDA states that a Labeler Code with no associated drug listings may be deactivated after two years.
Specified changes to Labeler Code information are not reported within FDA's current 30-day update timeframe.
A name change, merger/acquisition, or Labeler Code transfer is handled at the Labeler Code level but related product listings are left under outdated labeler information.
Registration, Labeler Code assignment, or NDC listing is marketed as FDA approval even though FDA expressly states that these identifiers do not denote approval.
The 2033 uniform NDC format is treated as if it already replaced today's native FDA-assigned 10-digit NDC system.
These services directly support the establishment, product, labeling, and import workflows that commonly follow or accompany a Labeler Code request.
Registration and annual renewal support for covered domestic and foreign drug establishments.
Prepare NDC product/package data and the associated SPL drug-listing submission.
Review drug labeling, active/inactive ingredient declarations, required statements, and listing/label consistency.
Help resolve DUNS information needed for drug establishment, Labeler Code, and listing workflows.
U.S. Agent representation for covered foreign drug establishments under the separate Part 207 requirement.
Verify current listing status and maintain product listing records without representing listing as FDA product approval.
DMF submission support for confidential manufacturing, chemistry, or ingredient information when appropriate.
Review drug DWPE/Import Alert issues, corrective evidence, and the alert-specific FDA pathway.
Direct answers about Labeler Codes, DUNS, SPL requests, FDA Direct, NDCs, private-label arrangements, updates, mergers, unused codes, OTC drugs, APIs, and the 2033 NDC transition.
A Drug Labeler Code is the FDA-assigned company identifier that forms the first segment used to create National Drug Codes. FDA states that the Labeler Code identifies the company marketing the drug.
FDA currently says generally only drug manufacturers and distributors need a Labeler Code. A company that does not manufacture or distribute drugs in the United States should not apply for one.
A Labeler Code must be assigned before a company can list a drug or reserve an NDC with FDA for the first time when that workflow requires a Labeler Code.
No. FDA explicitly states that a separate Labeler Code is not required for each establishment manufacturing a drug under that Labeler Code. A manufacturer with multiple establishments can use one Labeler Code for the company.
No. A Labeler Code identifies the company marketing the drug for NDC/listing purposes. An FEI identifies an FDA establishment/facility. They serve different functions.
No. The Labeler Code is the first segment used in an NDC. The full NDC also contains product and package segments.
No. FDA states that establishment registration or assignment of an NDC does not denote FDA approval of the company or its products. Marketing status must be established separately under the applicable drug pathway.
Labeler Code requests are part of 21 CFR Part 207. FDA's current request instructions reference the Part 207 Labeler Code/NDC drug-listing framework.
FDA uses Structured Product Labeling (SPL). FDA Direct includes CDER Direct functionality for drug registration/listing submissions, including NDC Labeler Code requests. Compatible SPL workflows may also be used under FDA's electronic submission instructions.
FDA's current instructions identify information including the company name, DUNS number, and contact information for the person responsible for receiving FDA communications related to drug listings under the Labeler Code, along with the other required SPL data.
FDA's current Labeler Code request instructions require the company DUNS number as part of the request information.
Yes. FDA's current instructions tell applicants to leave the NDC Labeler Code field blank on the initial Labeler Code request SPL.
FDA emails the assigned number to the contact on the request. The applicant must then submit an updated Labeler Code form SPL with the newly assigned number entered to complete the process.
FDA's current instructions state that no drugs can be listed under the assigned Labeler Code until the updated Labeler Code form SPL with the assigned number has been submitted to complete the process.
FDA's current public request instructions do not provide a guaranteed universal processing time. Timing can vary depending on submission validation, company/DUNS information, FDA review, and whether additional information is needed.
Preparation depends on having complete and accurate company, DUNS, and contact information. We prepare and submit the request promptly once the required information is available, but we do not guarantee FDA's assignment timeline.
Our standard professional fee is $349 per company for the Labeler Code request and confirmation scope described on this page.
No. The $349 is FDA Registration Assistance's professional service fee. FDA's Labeler Code request instructions do not identify a government filing fee for the standard request itself.
FDA's current instructions do not describe a routine annual Labeler Code renewal. However, FDA states that a Labeler Code with no associated drug listings may be deactivated after two years.
FDA states that under most circumstances an assigned Labeler Code with no NDCs listed within two years may be deactivated.
FDA currently says Labeler Code information must be updated within 30 days of changes to specified contact information, activities applicable to the entity, or the type of drugs for which the code will be used.
FDA's current instructions specifically address a Labeler Code transferring to another company through a merger or acquisition. Related product listings must also be updated with the new labeler name.
Not automatically. FDA's current instructions provide an update process for company-name changes and also require product listings under the Labeler Code to be updated with the new labeler name. The facts of a legal-entity change should be reviewed before assuming a new code is necessary.
No. FDA states that information updated in the Labeler Code request submission does not automatically populate or propagate to drug-listing files under that Labeler Code.
A representative can assist with preparing and submitting the SPL on behalf of the company, but the request should identify the correct company and company data that will hold/use the Labeler Code.
Yes, depending on their role. FDA describes the Labeler Code as identifying the company marketing the drug and says generally manufacturers and distributors need one. The specific private-label arrangement should be reviewed instead of assuming every brand owner automatically needs a separate code.
OTC drugs that must be listed need the applicable Labeler Code/NDC/listing workflow. Meeting the Labeler Code and listing requirements does not by itself establish that the OTC drug complies with the applicable monograph or other marketing-status requirements.
Yes. Labeler Codes are part of FDA's drug-listing/NDC framework and can be used for listed prescription drugs as applicable. Product approval and application requirements remain separate.
FDA's current drug-listing instructions include active pharmaceutical ingredient and other bulk-drug manufacturers among registered establishments that list drugs they produce for U.S. commercial distribution. A Labeler Code may therefore be needed for the applicable API/bulk-drug listing workflow.
Outsourcing facilities operate under a specialized compounding registration and product-reporting framework. FDA has separate 503B registration/product-reporting instructions, so their Labeler Code/NDC strategy should be reviewed under those rules rather than assuming the ordinary finished-drug workflow applies identically.
No universal answer should be assumed from ordinary Part 207 listing rules alone. Traditional pharmacy compounding can involve statutory exemptions and should be evaluated under the applicable Section 503A requirements and the pharmacy's actual activities.
The correct Labeler Code depends on which company is serving as the labeler/marketing company in the FDA listing structure. FDA's current guidance says the Labeler Code identifies the company marketing the drug, so the contract-manufacturing arrangement should be mapped before assigning the product's NDC.
Yes, generally. FDA states that a manufacturer with multiple establishments can use one Labeler Code because the code identifies the company marketing the product rather than each establishment.
A separate Labeler Code is not required for each drug. The same Labeler Code can be used as the company segment across its applicable NDCs; the product and package segments distinguish individual products/packages.
FDA continues to assign native 10-digit NDCs during the transition period through March 6, 2033. The current formats include 4-4-2, 5-3-2, and 5-4-1 configurations.
FDA's final rule takes effect March 7, 2033. The new native format will be a uniform 12-digit 6-4-2 configuration.
FDA states that it will automatically update drug-listing files to reflect the 12-digit NDC format on March 7, 2033. Registrants will update listing files as product labeling is updated to the new format.
No. FDA's NDC Directory contains information on active/certified listed drugs, including both approved and unapproved drugs. Inclusion in the directory does not mean the drug is FDA-approved.
No. Marketplace documentation policies are separate from FDA law and can change. A Labeler Code or NDC may be one piece of requested documentation, but it does not replace the product's applicable FDA marketing, labeling, manufacturing, and listing requirements.
Send the legal company name, country, DUNS number if available, responsible contact information, whether the company manufactures or distributes drugs in the United States, product type, existing establishment registration/FEI information if applicable, and whether you already have any Labeler Code or drug listings.
Tell us the legal company name, country, DUNS status, drug type, whether you manufacture or distribute the product, and whether you already have a drug establishment registration, FEI, or existing listings.